After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

But Mylan is a generics company; it doesn’t discover new medicines. Instead, it has poured its EpiPen windfalls into marketing and lobbying in an effort to expand adoption of its banner product.

D rug maker Mylan Pharmaceuticals, under fire from the public and Congress over the soaring price of its anaphylaxis treatment, will launch a generic version of the EpiPen auto-injector at a list ...

Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that has seen a price increase of more than 500% since 2007.

Mylan made $1.1 billion in revenue per year from EpiPen sales (though that may be decreasing with the introduction of new competition, including CVS’s generic auto-injector).

With Mylan N.V. MYL and Teva Pharmaceutical Industries Ltd. TEVA scheduled to report on May 10 and May 11, respectively, this may be a good time to consider which of these is the better stock.

Mylan has a board-election battle on its hands. Some powerful institutional investors are steamed about Mylan Chairman Robert Coury’s $97 million compensation in 2016—and they’re calling on ...